NewEdge Wealth’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.7M Buy
63,804
+29
+0% +$29.4K 0.7% 33
2025
Q4
$68.5M Buy
63,775
+6,387
+11% +$6.11M 0.77% 25
2025
Q3
$53.1M Sell
57,388
-9,982
-15% -$7.43M 0.76% 27
2025
Q2
$43.2M Sell
67,370
-1,335
-2% -$1.04M 0.68% 35
2025
Q1
$56.7M Sell
68,705
-11,694
-15% -$9.73M 1.03% 15
2024
Q4
$62.1M Buy
80,399
+6,103
+8% +$5.05M 1.08% 14
2024
Q3
$65.8M Buy
74,296
+10,319
+16% +$9.28M 1.19% 11
2024
Q2
$57.9M Sell
63,977
-2,705
-4% -$2.16M 1.25% 10
2024
Q1
$50.4M Sell
66,682
-10,075
-13% -$7.17M 1.13% 11
2023
Q4
$44.7M Buy
76,757
+9,070
+13% +$5.29M 1.14% 13
2023
Q3
$36.4M Buy
67,687
+6,123
+10% +$3.16M 1.15% 13
2023
Q2
$28.9M Buy
61,564
+8,002
+15% +$3.36M 0.96% 17
2023
Q1
$18.4M Buy
53,562
+2,589
+5% +$873K 0.7% 37
2022
Q4
$18.6M Buy
50,973
+2,628
+5% +$932K 0.8% 28
2022
Q3
$15.6M Buy
48,345
+5,028
+12% +$1.59M 0.74% 30
2022
Q2
$14M Buy
43,317
+42,102
+3,465% +$12.6M 0.64% 37
2022
Q1
$348K Buy
+1,215
New +$313K 0.02% 347

Other funds holding LLY

NewEdge Wealth's LLY Position: Q1 2026 in Review

NewEdge Wealth increased its Eli Lilly (LLY) stake by 0.05% in Q1 2026, buying an estimated $29.4K and bringing the position to 63,804 shares worth $58.7M. The position accounts for 0.7% of the portfolio, ranked #33.

NewEdge Wealth first reported a position in LLY in Q1 2022 and has held it in 17 quarters since. The position peaked at $68.5M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • NewEdge Wealth held 63,804 shares of Eli Lilly worth $58.7M as of Q1 2026.
  • NewEdge Wealth bought 29 Eli Lilly shares in Q1 2026, an estimated $29.4K.
  • Eli Lilly made up 0.7% of NewEdge Wealth's portfolio in Q1 2026, its #33 holding.
  • NewEdge Wealth first reported a position in Eli Lilly in Q1 2022 and has held it in 17 quarters since.
  • NewEdge Wealth's Eli Lilly position peaked at $68.5M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.